4b5
mAbexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 1998 (NCT00004184)
Timeline
1990s
- Jan 1, 1998
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Disialoganglioside GD2 other
Mimics the GD2 glycopeptide antigen eliciting both a humoral and cellular anti-GD2 immune response.
- Disialoganglioside GD2Immunity, passive
Disialoganglioside GD2 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109421 ↗
Also known as
- 4b5
- 4b5
- 4b5 anti-idiotype vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00004184 | Phase 1/Phase 2 (Phase 2) | Aug 1, 1998 | National Cancer Institute (NCI), University of Alabama, Birmingham, University of Louisville |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 1998 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 1998 |
| University of Louisville | Academic/Hospital | 1 | 0 | 1 | 1998 |
3 organizations
Page 1 / 1